Crispr Therapeutics (NASDAQ:CRSP) Reaches New 52-Week High at $74.00

Crispr Therapeutics AG (NASDAQ:CRSP) shares reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $74.00 and last traded at $72.61, with a volume of 447290 shares changing hands. The stock had previously closed at $73.13.

Several brokerages recently commented on CRSP. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $104.00 price objective on shares of Crispr Therapeutics in a research report on Tuesday, November 26th. Roth Capital boosted their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research note on Tuesday, November 19th. William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, November 19th. Finally, TheStreet raised shares of Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Crispr Therapeutics presently has an average rating of “Buy” and an average price target of $69.54.

The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $3.96 billion, a PE ratio of -20.97 and a beta of 3.30. The business’s 50-day simple moving average is $52.76 and its 200-day simple moving average is $46.89.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. Sell-side analysts forecast that Crispr Therapeutics AG will post 0.65 EPS for the current fiscal year.

In other news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now owns 7,500 shares in the company, valued at $390,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC raised its position in shares of Crispr Therapeutics by 5.9% in the second quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock worth $839,000 after acquiring an additional 986 shares during the period. Moody Aldrich Partners LLC acquired a new position in shares of Crispr Therapeutics during the 2nd quarter worth about $1,838,000. Traynor Capital Management Inc. purchased a new position in Crispr Therapeutics in the 2nd quarter valued at about $308,000. Nikko Asset Management Americas Inc. lifted its stake in Crispr Therapeutics by 324.3% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock valued at $88,143,000 after buying an additional 1,430,364 shares in the last quarter. Finally, BNP Paribas Arbitrage SA acquired a new stake in Crispr Therapeutics in the 2nd quarter worth about $41,000. 49.81% of the stock is owned by institutional investors.

Crispr Therapeutics Company Profile (NASDAQ:CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: What is a Real Estate Investment Trust (REIT)?

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.